AI 热点

Isomorphic Labs 完成 50 亿美元 C 轮融资,推进药物候选进入临床试验

TechCrunch AI更新于 11月18日 00:01

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

AI 导读

从 Google DeepMind 分拆出来的 AI 药物发现平台 Isomorphic Labs 完成 50 亿美元 C 轮融资,由 Greenoaks 和 Sequoia Capital 联合领投,Andreessen Horowitz 及 Alphabet 旗下 GV、Capital G 等原有投资方参投。公司称其基于 AlphaFold 的 AI 药物设计引擎在肿瘤和免疫领域取得积极的临床前结果,并与 Eli Lilly、Novartis、Johnson & Johnson 达成合作。本轮资金将用于继续开发药物设计引擎并拓展更多药物类型,公司未披露最新估值,Bloomberg 此前报道其寻求以 500 亿美元估值融资。

推荐理由

AI 评分 68

Isomorphic Labs 在 5 月完成 21 亿美元 B 轮后再融 50 亿美元,读者可据此观察 AI 制药从模型走向临床试验的资金节奏。

主题

标签

正文

Isomorphic Labs , the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials.

The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, also invested.

Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models that explore various areas of chemistry to help the company design drugs. The company, whose work builds on DeepMind’s breakthrough AlphaFold protein-folding AI model , said its program has yielded “positive preclinical results” in oncology and immunology. The lab has struck deals with pharma giants like Eli Lilly, Novartis, and Johnson & Johnson.

The new funding, which comes on the heels of a $2.1 billion Series B round in May, will be used to continue developing its drug-design engine, as well as to foray into more types of medicine.

The Series C is Isomorphic’s first fundraise since its founder and CEO, Demis Hassabis, left his position as head of DeepMind to focus on drug discovery, which also saw him moving into a chairman role at DeepMind. Hassabis and then-director of DeepMind John Jumper won the Nobel Prize in chemistry for the lab’s work on AlphaFold, a system that predicts the 3D structure of proteins with nothing more than their genetic sequence.

Isomorphic did not disclose its new valuation. Bloomberg reported earlier this month that the lab was looking to raise funding at a $50 billion valuation.

来源

TechCrunch AI